Mechanism of Action
Rev-Erb is a nuclear receptor involved in circadian rhythm regulation and metabolic processes. SR9009 activates Rev-Erb, producing effects on fat storage, glucose metabolism, and mitochondrial biogenesis. Animal studies show dramatic endurance improvements and fat loss. The critical unknown is that SR9009 was never demonstrated to be orally bioavailable in humans — the animal studies used injection. Oral SR9009 may produce no effect at all due to rapid first-pass metabolism.
Ester Profile
Non-steroidal oral compound with extremely poor and uncertain oral bioavailability in humans. The short half-life of 4-6 hours requires multiple daily doses. Whether those doses produce any systemic effect in humans via oral administration has not been established.
How It's Used in Fitness
SR9009 is marketed and used in performance settings for endurance enhancement and fat loss, specifically as an alternative to Cardarine after Cardarine's cancer findings became widely known. The appeal is the same — improved endurance and fat oxidation without androgenic effects. The fundamental problem is that the human oral bioavailability question has never been resolved, meaning users may be taking an expensive compound that produces no effect.
Stacking Context
SR9009 appears in stacks alongside SARMs or traditional anabolics as an endurance and fat loss addition. It is most commonly combined with Ostarine or RAD-140 in users who want the full SARM-plus-metabolic-enhancer experience. Given the bioavailability uncertainty, its contribution to any stack is genuinely unknown.
Medical Use
- No approved human use
- No human clinical trials of any phase
- All efficacy data is from animal injection studies
Side Effects
- Unknown safety profile — no human trial data
- Potential circadian rhythm disruption with chronic use
- Unknown immune system effects from Rev-Erb modulation
- Nausea reported
- Insomnia from circadian effects
- Oral bioavailability in humans unestablished — compound may produce no effect
What Actually Goes Wrong
The primary risk with SR9009 is the complete absence of human safety data combined with the bioavailability uncertainty. If it is not bioavailable orally, users are wasting money and ingesting an untested compound with no benefit. If it is bioavailable, the safety profile is entirely unknown. Rev-Erb is involved in immune function, inflammation regulation, and circadian biology — modulating it chronically has unknown downstream consequences.
Detection Window
WADA bans Rev-Erb agonists. Detection methodology limited.
SR9009 is the compound where the most fundamental question — does it even work when taken orally by humans — has never been answered. The animal studies are injection-based. The human anecdotal reports are inherently unreliable because placebo effects and other protocol variables cannot be separated from the compound's effects. It is possible that the endurance improvements people report while taking SR9009 are real and attributable to something else entirely in their protocol.